BACKGROUND: Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridium. difficile infection (rCDI). FMT capsules have emerged, and it is unknown if delivery location and dose impact efficacy. METHODS: We compared two cohorts of patients receiving two capsule formulations: gastric release (FMTgr) and targeted colonic release (FMTcr) at two different sites. Cohort A received FMTgr at (1) high dose: 60 capsules and low dose: 30 capsules. Patients in Cohort B received FMTcr at (1) high dose: 30 capsules (2) low dose: 10 capsules. Clinical cure rates and adverse events were monitored through week 8. Paired t-tests were used to compare diversity pre- and post-FMT. RESULTS: 51 rCDI patients were enrolled. Cohort A contained n = 20 and Cohort B contained n = 31. Overall cure at week 8 for FMTgr was 75% (15/20) compared to 80.6% for FMTcr, (25/31), p = 0.63. Both formulations were safe with no serious adverse events. FMTcr was superior at increasing gut microbial diversity. DISCUSSION: To our knowledge, this is the first study to compare targeted delivery of FMT capsules. While both capsules were safe and efficacious, microbial engraftment patterns were superior in FMTcr.
BACKGROUND: Fecal microbiota transplantation (FMT) is an effective therapy for recurrent Clostridium. difficileinfection (rCDI). FMT capsules have emerged, and it is unknown if delivery location and dose impact efficacy. METHODS: We compared two cohorts of patients receiving two capsule formulations: gastric release (FMTgr) and targeted colonic release (FMTcr) at two different sites. Cohort A received FMTgr at (1) high dose: 60 capsules and low dose: 30 capsules. Patients in Cohort B received FMTcr at (1) high dose: 30 capsules (2) low dose: 10 capsules. Clinical cure rates and adverse events were monitored through week 8. Paired t-tests were used to compare diversity pre- and post-FMT. RESULTS: 51 rCDI patients were enrolled. Cohort A contained n = 20 and Cohort B contained n = 31. Overall cure at week 8 for FMTgr was 75% (15/20) compared to 80.6% for FMTcr, (25/31), p = 0.63. Both formulations were safe with no serious adverse events. FMTcr was superior at increasing gut microbial diversity. DISCUSSION: To our knowledge, this is the first study to compare targeted delivery of FMT capsules. While both capsules were safe and efficacious, microbial engraftment patterns were superior in FMTcr.
Authors: James J Kozich; Sarah L Westcott; Nielson T Baxter; Sarah K Highlander; Patrick D Schloss Journal: Appl Environ Microbiol Date: 2013-06-21 Impact factor: 4.792
Authors: Christopher Staley; Matthew J Hamilton; Byron P Vaughn; Carolyn T Graiziger; Krista M Newman; Amanda J Kabage; Michael J Sadowsky; Alexander Khoruts Journal: Am J Gastroenterol Date: 2017-02-14 Impact factor: 10.864
Authors: M J T Crobach; T Planche; C Eckert; F Barbut; E M Terveer; O M Dekkers; M H Wilcox; E J Kuijper Journal: Clin Microbiol Infect Date: 2016-07-25 Impact factor: 8.067
Authors: Gert Van Assche; Geert D'Haens; Maja Noman; Séverine Vermeire; Martin Hiele; Katrien Asnong; Joris Arts; Andre D'Hoore; Freddy Penninckx; Paul Rutgeerts Journal: Gastroenterology Date: 2003-10 Impact factor: 22.682
Authors: Christopher R Polage; Clare E Gyorke; Michael A Kennedy; Jhansi L Leslie; David L Chin; Susan Wang; Hien H Nguyen; Bin Huang; Yi-Wei Tang; Lenora W Lee; Kyoungmi Kim; Sandra Taylor; Patrick S Romano; Edward A Panacek; Parker B Goodell; Jay V Solnick; Stuart H Cohen Journal: JAMA Intern Med Date: 2015-11 Impact factor: 21.873
Authors: Siew C Ng; Michael A Kamm; Yun Kit Yeoh; Paul K S Chan; Tao Zuo; Whitney Tang; Ajit Sood; Akira Andoh; Naoki Ohmiya; Yongjian Zhou; Choon Jin Ooi; Varocha Mahachai; Chun-Ying Wu; Faming Zhang; Kentaro Sugano; Francis K L Chan Journal: Gut Date: 2019-10-14 Impact factor: 23.059
Authors: Adrian H Teruel; Isabel Gonzalez-Alvarez; Marival Bermejo; Virginia Merino; Maria Dolores Marcos; Felix Sancenon; Marta Gonzalez-Alvarez; Ramon Martinez-Mañez Journal: Int J Mol Sci Date: 2020-09-05 Impact factor: 5.923